Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 3, 2014, Pages

  Gotha, Lara ^a   Lim, Sang Yup ^a,f   Osherov, Azriel B ^a   Wolff, Rafael ^a   Qiang, Beiping ^a   Erlich, Ilana ^a   Nili, Nafiseh ^a   Pillarisetti, Sivaram ^c   Chang, Ya Ting ^e   Tran, Phan Kiet ^d   Tryggvason, Karl ^e   Hedin, Ulf ^e   Tran Lundmark, Karin ^e   Advani, Suzanne L ^b   Gilbert, Richard E ^b   Strauss, Bradley H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Dr Reddy's Laboratories   (Georgia)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Korea University   (South Korea)

Author keywords

Arterial injury; Heparan sulfate proteoglycans; Perlecan; Smooth muscle cells

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; HEPARAN SULFATE; PERLECAN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; PROTEOHEPARAN SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CELL ACTIVITY; CELL FUNCTION; CELL INFILTRATION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; WILD TYPE; ANIMAL; C57BL MOUSE; CAROTID ARTERY; CELL ADHESION; CELL CULTURE; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GENOTYPE; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PATHOLOGY; PHENOTYPE; STRUCTURE ACTIVITY RELATION; TIME; TRANSGENIC MOUSE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

ANIMALS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 2; GENOTYPE; HEPARAN SULFATE PROTEOGLYCANS; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-SIS; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; VASCULAR REMODELING; VASCULAR SYSTEM INJURIES;

EID: 84905223350     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00654.2013     Document Type: Article

References (32)

1. Bar-Shavit R, Maoz M, Ginzburg Y, Vlodavsky I. Specific involvement of glypican in thrombin adhesive properties. J Cell Biochem 61: 278-291, 1996.
2. Benhamron S, Nechushtan H, Verbovetski I, Krispin A, Abboud-Jarrous G, Zcharia E, Edovitsky E, Nahari E, Peretz T, Vlodavsky I, Mevorach D. Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells. J Immunol 176: 6417-6424, 2006.
3. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal regulated kinases 1 and 2. Circ Res 94: 316-323, 2004.
4. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265: 625-626, 1977.
5. Fritze LM, Reilly CF, Rosenberg RD. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 100: 1041-1049, 1985.
6. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res 94: 175-183, 2004.
7. Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274: 10816-10822, 1999.
8. Hollenbeck ST, Nelson PR, Yamamura S, Faries PL, Liu B, Kent KC. Intracellular calcium transients are necessary for platelet-derived growth factor but not extracellular matrix protein-induced vascular smooth muscle cell migration. J Vasc Surg 40: 351-358, 2004.
9. Hou G, Mulholland D, Gronska MA, Bendeck MP. Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury. Am J Pathol 156: 467-476, 2000.
10. Kinsella MG, Irvin C, Reidy MA, Wight TN. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 175: 51-57, 2004.
11. Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, Wight TN. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol 23: 608-614, 2003.
12. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res 83: 305-313, 1998.
13. Lundmark K, Tran PK, Kinsella MG, Clowes AW, Wight TN, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J Cell Physiol 188: 67-74, 2001.
14. Matsuura R, Isaka N, Imanaka-Yoshida K, Yoshida T, Sakakura T, Nakano T. Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty. J Pathol 180: 311-316, 1996.
15. Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z, Vlodavsky I. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 76: 1306-1313, 1985.
16. Nugent MA, Karnovsky MJ, Edelman ER. Vascular cell-derived heparin sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res 73: 1051-1060, 1993.
17. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 6: 633-643, 2006.
18. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 10: 1312-1318, 1996.
19. Rossi M, Morita H, Sormunen R, Airenne S, Kreivi M, Wang L, Fukai N, Olsen BR, Tryggvason K, Soininen R. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 22: 236-245, 2003.
20. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101: 731-736, 1998.
21. Ruoslahti E. Structure and biology of proteoglycans. Annu Rev Cell Biol 4: 229-255, 1988.
22. Sakakibara K, Liu B, Hollenbeck S, Kent KC. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 288: H2861-H2868, 2005.
23. Sasaki N, Higashi N, Taka T, Nakajima M, Irimura T. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. J Immunol 172: 3830-3835, 2004.
24. Segev A, Nili N, Osherov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH. A perlecan inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan. EuroIntervention 6: 134-140, 2010.
25. Segev A, Nili N, Strauss BH. The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res 63: 603-610, 2004.
26. Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M, Saruta T. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 94: 1067-1074, 2004.
27. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79: 1015-1024, 1994.
28. Tran PK, Tran-Lundmark K, Soininen R, Tryggvason K, Thyberg J, Hedin U. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res 94: 550-558, 2004.
29. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12: 112-127, 1992.
30. Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MC. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell 14: 1941-1952, 2003.
31. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 18: 163-178, 1999.
32. Zhu B, Kuhel DG, Witte DP, Hui D. ApolipoproteinE inhibits neointimal hyperplasia after arterial injury in mice. Am J Pathol 157: 1839-1848, 2000.